Month: June 2020

3. jūnijā AS „Olainfarm” aizvadīja virtuālo konferenci investoriem. Konferences laikā AS „Olainfarm” valdes priekšsēdētājs Jerūns Veitess (Jeroen Weites) un Investoru attiecību konsultants Jānis Dubrovskis analizēja 2020. gada 1. ceturkšņa finanšu rezultātus, kā arī informēja par citām aktualitātēm uzņēmumā.Virtuālās konferences ieraksts ir pieejams šeit: https://bit.ly/3duZILX. Savukārt virtuālās konferences laikā demonstrētā prezentācija ir pievienota paziņojuma pielikumā. Alternatīvo snieguma rādītāju aprēķina metodika ir atklāta 2019.gada pārskatā (21.lpp.).Olainfarm pateicas visiem, kas piedalījās vebinārā un aicina sekot līdz informācijai par nākamo virtuālo konferenci!AS „Olainfarm“ ir viens no lielākajiem uzņēmumiem Baltijas valstīs ar vairāk nekā 45 gadu pieredzi medikamentu un ķīmiski farmaceitisko produktu ražošanā. Kompānijas...

GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported publication in the journal Fertility and Sterility of “Gonadotropin-releasing Hormone Antagonist (linzagolix): a New Therapy for Uterine Adenomyosis,” a case report from a pilot study assessing the use of linzagolix for the treatment of uterine adenomyosis.Adenomyosis is an estrogen-driven condition in which endometrial tissue (inner uterine lining) is present within the myometrium (muscular uterine wall), resulting in uterine enlargement, heavy menstrual bleeding, dysmenorrhea (painful menses) and infertility. Adenomyosis affects between 20 and 35% of reproductive-aged women, and may co-exist with endometriosis and/or...

 — Integrated Safety Analysis from the Phase 3 FINCH and Phase 2 DARWIN Programs Informs Long-Term Safety Profile of Filgotinib in RA —— Data Presented at The European League Against Rheumatism, EULAR, European E-Congress of Rheumatology 2020 —Foster City, Calif., & Mechelen, Belgium, 4 June, 2020, 07.00 CET – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced Week 52 results from the Phase 3 FINCH 1 and FINCH 3 studies of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately to severely active rheumatoid arthritis (RA). The data demonstrate sustained efficacy and a consistent safety profile with up to 52 weeks of filgotinib treatment across RA patient populations. The new data are among 15 abstracts on filgotinib in RA that...

 — Geïntegreerde veiligheidsanalyse van de fase 3 FINCH- en fase 2 DARWIN-studies geeft veiligheidsprofiel van filgotinib bij reuma op lange termijn aan —— Data gepresenteerd op EULAR (European League Against Rheumatism), European E-congress of Rheumatology 2020 —Foster City, Californië & Mechelen, België, 4 juni 2020, 07.00 CET – Gilead Sciences, Inc. (Nasdaq: GILD) en Galapagos NV (Euronext & Nasdaq: GLPG) kondigden vandaag 52 weken resultaten aan van hun gezamenlijke FINCH 1 en FINCH 3-studies voor filgotinib, een orale, selectieve JAK1-remmer in onderzoek, bij volwassenen met matige tot ernstige actieve reumatoïde artritis. De gegevens tonen een aanhoudende werkzaamheid en een consistent veiligheidsprofiel aan voor de 52 weken behandeling met filgotinib bij reumapatiëntenpopulaties. De nieuwe...

Transaction provides up to CHF 20.0 million in near-term liquidityFinancing provides funding runway to advance DMD-franchise with Puldysa® and vamorolonePratteln, Switzerland, June 4, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that it has entered into a commitment letter for a financing facility providing for the issuance of senior secured exchangeable notes to an investment fund managed by Highbridge Capital Management, LLC, an existing investor in the Company. The financing instrument would make available up to CHF 20.0 million in near-term liquidity to Santhera and is expected to provide a runway to advance value-enhancing development and pre-commercialization activities for the neuromuscular compounds Puldysa® and vamorolone.“This financing will immediately improve Santhera’s liquidity and allow us to pursue our operational...

Transaktion stellt bis zu CHF 20.0 Millionen an kurzfristiger Liquidität zur VerfügungFinanzierung bietet Mittel zur Weiterentwicklung der DMD-Franchise mit Puldysa® und Vamorolone Pratteln, Schweiz, 4. Juni 2020 – Santhera Pharmaceuticals (SIX: SANN) gibt den Abschluss einer Verpflichtungserklärung für eine Finanzierungsfazilität bekannt, welche die Ausgabe von vorrangig besicherten Wandelschuldverschreibungen an einen von Highbridge Capital Management, LLC, einem bestehenden Investor des Unternehmens, verwalteten Anlagefonds vorsieht. Das Finanzierungsinstrument würde Santhera kurzfristig bis zu CHF 20.0 Millionen an liquiden Mitteln zur Verfügung stellen und soll es ermöglichen, wertsteigernde Aktivitäten in der Entwicklung sowie im Vorfeld der Kommerzialisierung für die neuromuskulären Wirkstoffe Puldysa® und Vamorolone voranzutreiben.„Diese...

FDA EUA1 now makes IL-6 testing accessible to patients in the United States to assist in identifying severe inflammatory response in patients with confirmed COVID-19 and is also available in markets accepting the CE-mark2Interleukin 6 (IL-6) is an early indicator for acute inflammation to aid in the management of critically ill patientsThis test is available on Roche’s cobas e analysers which are widely available around the world             Basel, 04 June 2020  – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorisation (EUA) for the Elecsys® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and can be used to help identify patients with confirmed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. AttachmentRoche_mediarelease_IL-6...

EMERYVILLE, Calif., June 04, 2020 (GLOBE NEWSWIRE) — NMI Holdings, Inc. (Nasdaq:NMIH) (the “Company”) today announced the pricing of an underwritten registered public offering of 13,800,000 shares of Class A common stock, par value $0.01 per share, at a public offering price of $14.50 per share (the “offering”). The offering was increased from the previously announced offering size of 10,000,000 shares of Class A common stock. In connection with the offering, the underwriters have a 30-day option to purchase up to 2,070,000 additional shares of Class A common stock at the public offering price, less underwriting discounts and commissions, from the Company. The offering is expected to close on June 8, 2020, subject to customary closing conditions.  The Company expects net proceeds of this offering, after deducting underwriting discounts...

VANCOUVER, British Columbia, June 04, 2020 (GLOBE NEWSWIRE) — Isracann Biosciences Inc.  (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer is pleased by the recent government approval permitting the export of cannabis for sale to foreign medicinal markets.On May 13, 2020, the Israeli Ministry of Economy signed a Free Export Order for medical cannabis products. The order allows the government to implement a medical cannabis decision that was previously signed in 2019. The order was announced to go into effect 30 days from the signing, at which time licensed producers of medical cannabis in Israel will be able to apply for an export permit to ship product to international markets. Accordingly, Isracann has tasked its...

SHENZHEN, China, June 04, 2020 (GLOBE NEWSWIRE) — LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading online consumption and consumer finance platform for educated young professionals in China, today announced its unaudited financial results for the quarter ended March 31, 2020.First Quarter 2020 Operational Highlights:Total loan originations1 in the first quarter of 2020 reached RMB34.1 billion, an increase of 69.5% from RMB20.1 billion in the first quarter of 2019.Total outstanding principal balance of loans1 reached RMB58.5 billion as of March 31, 2020, representing an increase of 67.2% from RMB35.0 billion as of March 31, 2019.Number of active users2 who used our loan products in the first quarter of 2020 reached 6.4 million, representing an increase of 99.1% from 3.2 million in the first quarter of...